Answers are grounded in this paper and cite their sources.
For patients who have rapidly progressive dementia and are strongly suspected of having sCJD and for whom diagnosis remains uncertain (pretest probability ∼20%-90%), clinicians should order CSF 14-3-3 assays to reduce the uncertainty of the diagnosis (Level B).
No takes yet. Share an insight, caveat, or question.
Muayqil et al. (2012) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: